Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

In the PALOMA-3 trial, the median progression-free survival (PFS) was longer among patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) treated with palbociclib plus fulvestrant than those treated with placebo plus fulve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jee Hyun, Im, Seock-Ah, Sim, Sung Hoon, Bananis, Eustratios, Huang, Xin, Kim, Hyun Seon, Kim, Sung-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920865/
https://www.ncbi.nlm.nih.gov/pubmed/33634624
http://dx.doi.org/10.4048/jbc.2021.24.e13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920865/
https://www.ncbi.nlm.nih.gov/pubmed/33634624
http://dx.doi.org/10.4048/jbc.2021.24.e13

Ejemplares similares